That is flagrantly, obviously and indisputably false!
RE"There have been NO long-term safety studies on vaccines"
Vaccines go thru all Phases of clinical trials: Phase I, II's and III's. In addition, monitoring for problems continues long after a vaccine is approved, exactly as is done with drugs.
I am at a complete loss as to imagine where you could have gotten such a completely false idea. (or maybe not, but I'm not going there)
Perhaps you care to enlighten us as to your source for that "interesting" bit of "information"?
PS Modern adjuvants do not accumulate and have no inherent tendency to toxicity (as do mercury and aluminum) I suggest that you check out Novavax's "Matrix-M" adjuvant for an example of an adjuvant many times for effective than the older ones, with no evidence whatsoever of safety problems and thoroughly excreted from the body after use.
and, one more time, since you appear to be having remarkable difficultly getting this: I never on any occasion whatsoever in any way whatsoever either said or implied that "we shouldn't develop treatments because people ought to be able to avoid" something. NOR has anyone else on this board said or implied any such thing. That's a pure straw dog of your own creation.
In addition, no one has said anything remotely like "vaccines will prevent all disease" AH! But you weren't actually saying that anyone was saying it, only IMPLYING that someone was saying it. How utterly disingenuous. As are your repeated attempts to mislabel vaccines as an "off topic" subject. Serious competition for a company's markets is always HIGHLY relevant discussion. And it's very well known that an effective vaccine can enormously reduce the number of infections from a disease - by many orders of magnitude - a hundred times is not at all uncommon. How you could honestly imagine that vaccines are not a relevant topic is completely beyond me.
Vaccines are, and always will be, a serious potential competitor for nanoviricides' markets. This is especially true given that new vaccine technologies (like NVAX's VLP technology for example) are able to address vaccine targets that were totally resistant to the old vaccine technologies (RSV and the neuraminidase target for influenzas*1, for example, which NVAX has shown data for that was so outstanding it got a publication of intermim Phase I results in the NEJM despite them having a long standing policy against publishing any Phase I results much less interim Phase I)
*1 which has massive implications for the potential market for Flucide. And NVAX's quadrivalent seasonal influenza vaccine (and its H7N9 vaccine and more) are years closer to commercialization that Flucide. seasonal has done multiple Phase II's already and H7N9 will complete a Phase I/II (already fast tracked) in May this year.
